Alpha Sense BI

MAY 5, 2023

After three volatile years, rife with challenging macroeconomic conditions — from a global pandemic and wars to far-reaching supply chain issues — the M&A space has its fair share of ups and downs. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.

Biotech 97

Biotech Capital Banking Startups 97

Sedulo

MARCH 15, 2023

Our analysis of global data gathered from multiple trial registries provided a compelling snapshot of the recent IO clinical landscape and prompted several unanswered questions regarding future evolution and the impact on manufacturers competing in the space.

Biotech 52

Biotech Competitive Landscape Pharmaceutical Benchmarking 52

Alpha Sense BI

APRIL 29, 2024

Instead, investors will likely turn to innovative start-up companies with promising growth plans and strong leadership teams. One VC sustainability investor in particular set forth a plan to reduce 10% of global carbon emissions by 2035 by investing in 100×100 companies.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

APRIL 19, 2024

2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion. On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. In fact, projections for the global spatial computing market are valued at $269.8 billion by 2032.

Technology 69

Technology Technology Retail Biotech 69

Engage3

MAY 19, 2022

Ken served on the Board of Directors of Revionics between 2007-2011 and as Chief Scientist & VP of Innovations at SAP AG between 2006-2007. Tim Ouimet Founder & Board Observer Tim Ouimet is a Founder and Board Member at Engage3 and is a recognized industry innovator in retail pricing strategies.

Retail 52

Retail Capital Finance Biotech 52

Alpha Sense BI

JANUARY 26, 2024

We believe that this focus on accessibility and sustainability represents an alternative and attractive opportunity in supporting innovative solutions for global healthcare challenges. This renewed interest in rare disease therapeutics can be attributed to the U.S.

Biotech 59

Biotech Research Loss Algorithm 59

Wink Intel

FEBRUARY 23, 2021

We are excited to continue working with leading global financial institutions to further round out our fixed index annuity portfolio,” said American Equity Chief Executive Officer Anant Bhalla. tech and biotech ETFs and two fixed income components. New Rider Option. Clients now have a new option for magnified growth potential.

Intellectual Property 40

Intellectual Property Biotech Banking Retail 40

CIO

JULY 30, 2024

The launch of ChatGPT in November 2022 set off a generative AI gold rush, with companies scrambling to adopt the technology and demonstrate innovation. Some biotech and pharma companies, including Johnson & Johnson , are promoting gen AI as the next big thing in drug discovery.

Biotech 542

Biotech Business Pharmaceutical Finance 542

CIO

MARCH 4, 2025

CEOs, CIOs and CFOs are finding that deep tech is actively driving business innovation and profitability. Biotechnology and synthetic biology: The swift development of mRNA vaccines in 2020 illustrated biotechs unprecedented speed in delivering transformative products. It was hard to imagine this pace 5-10 years ago.

Technology 442

Technology Technology Biotech Business 442

CIO

APRIL 3, 2025

At Biogen, she helped revolutionize the organizations digital capabilities in the highly regulated biotech industry. She then took on the challenge of leading IT and digital transformation at National Grid, a $20 billion multinational power utility, where she drove strategic initiatives and innovation at the highest level.

Biotech 462

Biotech IT Travel Win 462

CIO

NOVEMBER 25, 2024

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. I’ve had many great positions throughout my career, in many different industries, from biotech to pharma to tech software companies, and currently at a medical device company.

Biotech 458

Biotech Matrix Learning Security 458

Alpha Sense BI

MARCH 13, 2024

According to PwC’s Annual Global CEO survey, 54% of healthcare industry CEOs intend to make at least one acquisition in the next three years. According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs.

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59

Alpha Sense BI

MARCH 14, 2025

While lingering concerns around tariffs and global policy pose macroeconomic uncertainty, experts widely agree that 2025 will mark a widespread return to IPO and deal activity , following years of low activity. If you are a GSK or a Pfizer or even an even smaller start-up biotech , exactly the same criteria is applied across.

Capital 59

Capital Biotech Startups Finance 59

Alpha Sense BI

FEBRUARY 6, 2025

In 2024, global M&A volume reached $3.4 North America led global M&A activity with 50% of deal volume, followed by EMEA at 25% and APAC at 22%. The tech sector accounted for 19% of global deal volume, followed by healthcare at 10% and finance at 9%. trillion seen in 2021. Novo Holdings Acquisition of Catalent: $16.5

Biotech 59

Biotech Capital Pharmaceutical Finance 59

ATTEST

NOVEMBER 22, 2024

Boston’s innovation business ecosystem—from biotech startups in Kendall Square to fintech firms downtown—relies heavily on quality consumer insights. This modern approach aligns perfectly with Boston’s innovation-driven business culture.

Market Research 52

Market Research Marketing Research Research Marketing 52

Alpha Sense BI

APRIL 3, 2025

Concurrently, smaller biotech firms and midsized companies offering promising innovations, particularly in high-demand therapeutic areas such as oncology, immunology, neuroscience, and cardio-metabolic conditions, are expected to become highly attractive targets. How will tariff policies play out?

Biotech 52

Biotech Pharmaceutical Loss Research 52

ATTEST

DECEMBER 20, 2024

From biotech startups in Torrey Pines to craft breweries in North Park, San Diego businesses rely on solid consumer insights to guide their decisions. Attest – Best for fast, reliable consumer and market insights Attest revolutionizes market research through an innovative combination of advanced platform and expert research support.

Market Research 52

Market Research Marketing Research Research Marketing 52

Alpha Sense BI

JANUARY 8, 2025

At the same time, the outlook for therapeutic innovation remains bright. RFK), have clouded 2025 visibility for the healthcare sector and generated a mix of expectations for healthcare systems and providers, health insurers, and biotech/pharma companies. Kennedy Jr. What] makes it significantly worse is how the public reacted.

Innovation 69

Innovation Biotech Pharmaceutical Benchmarking 69